- Imatinib, sold
under the
brand names Gleevec and
Glivec (both
marketed worldwide by Novartis)
among others, is an oral
targeted therapy medication used...
- deal),
carbamazepine (Tegretol),
valsartan (Diovan),
imatinib mesylate (
Gleevec/Glivec),
cyclosporine (Neoral/Sandimmune),
letrozole (Femara), methylphenidate...
- the
Indian Supreme Court on the
issue of
whether Novartis could patent Gleevec in India, and was the
culmination of a seven-year-long
litigation fought...
- most
successful molecular targeted therapeutics is imatinib,
marketed as
Gleevec,
which is a
kinase inhibitor with
exceptional affinity for the oncofusion...
-
number of
children also
develop this disease. It is
treated with
imatinib (
Gleevec in
United States,
Glivec in Europe) or
other drugs. The five-year survival...
-
imatinib (
Gleevec), the
first medication that
specifically targets cancer cells, for the
treatment of
chronic myeloid leukemia (CML). In 2001,
Gleevec gained...
- The
first of this new
class of
drugs was
imatinib mesylate (marketed as
Gleevec or Glivec),
approved by the US Food and Drug
Administration (FDA) in 2001...
- life. Abdul-Jabbar is a
spokesman for Novartis, the
company that
produces Gleevec, his
cancer medication. In
February 2011, Abdul-Jabbar
announced via Twitter...
- respectively,
using ISCN standards. In the late 1990s, STI-571 (imatinib,
Gleevec/Glivec) was
identified by the
pharmaceutical company Novartis (then known...
-
inhibitor (IAPs). The
addition of
agents such as Herceptin, Iressa, or
Gleevec works to stop
cells from
cycling and
causes apoptosis activation by blocking...
